Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors

被引：0
|
作者：
Zhang, Yan
Zhou, Lin
Gong, Youling
Huang, Meijuan
Tang, Min
Liu, Yongmei
Yu, Min
Xiu, Weigang
Liang, Xinjun
Liu, Xinyu
Fu, Xin-Yuan
Lu, You
机构：
[1] Sichuan Univ, Dept Thorac Oncol, Canc Ctr, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Thorac Oncol Ward, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[4] West China Hosp, Sch Med, Dept Thorac Oncol, Canc Ctr, Chengdu, Peoples R China
[5] Hubei Canc Hosp, Dept Med Oncol, Wuhan, Peoples R China
[6] GenEros Biopharma Ltd, Clin Dev Dept, Hangzhou, Peoples R China
[7] Sichuan Univ, Inst Human Dis & Immunotherapy, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9112
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A phase I study of the safety, tolerability and pharmacokinetics of pazopanib (P) in combination with gemcitabine (G) for advanced solid tumors
    Richly, H.
    Rubin, S. D.
    Madi, A.
    Jeffels, M.
    Nokay, B.
    Gibson, D.
    Weller, S.
    Scheulen, M. E.
    Plummer, R.
    EJC SUPPLEMENTS, 2010, 8 (07): : 25 - 25
  • [42] Phase I study of safety, tolerability, and pharmacokinetics of pazopanib in combination with oral topotecan in patients with advanced solid tumors
    Kerklaan, Bojana Milojkovic
    Lolkema, Martijn P. J. K.
    Devriese, Lot A.
    Voest, Emile E.
    Nol-Boekel, A.
    Mergui-Roelvink, M.
    Mykulowycz, Kristine
    Stoebenau, Joseph E.
    Fang, Lei
    Legenne, Philippe
    Wissel, Paul Stephen
    Smith, Deborah A.
    Giantonio, Bruce J.
    Schellens, Jan H. M.
    Witteveen, Petronella
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
    Weekes, Colin
    Lockhart, A. Craig
    Lee, James J.
    Sturm, Isrid
    Cleton, Adriaan
    Huang, Funan
    Lenz, Heinz-Josef
    INTERNATIONAL JOURNAL OF CANCER, 2019, 145 (09) : 2450 - 2458
  • [44] A phase I study of the safety, tolerability, and pharmacokinetics of intravenous XMT-1001 in patients with advanced solid tumors
    Sausville, Edward A.
    Anthony, Stephen P.
    Garbo, Lawrence E.
    Shkolny, Dana
    Yurkovetskiy, Alex V.
    Bethune, Claudette
    Schwertschlag, Ullrich
    Fram, Robert J.
    MOLECULAR CANCER THERAPEUTICS, 2007, 6 (12) : 3383S - 3383S
  • [45] A phase I study to assess the safety, tolerability and pharmacokinetics of the ErbB-family inhibitor ARRY-334543 in patients with advanced solid tumors
    Hotte, Sebastien J.
    Hirte, Hal W.
    Turner, Sandra
    Jonker, Derek
    Fortin, Catherine
    Barrett, Emma
    Freeman, Burgess
    Kass, Carrie
    Zacharias, Katherine
    Chow, Laura Q. M.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [46] A phase lb study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
    Weekes, Colin
    Lockhart, A. Craig
    Lenz, Heinz-Josef
    Lee, James J.
    Cleton, Adriaan
    Huang, Funan
    Sturm, Isrid
    CANCER RESEARCH, 2016, 76
  • [47] D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
    Li, Ziming
    Song, Zhengbo
    Zhao, Yanqiu
    Wang, Pingli
    Jiang, Liyan
    Gong, Yi
    Zhou, Jianying
    Jian, Hong
    Dong, Xiaorong
    Zhuang, Wu
    Cang, Shundong
    Yang, Nong
    Fang, Jian
    Shi, Jianhua
    Lu, Junguo
    Ma, Rui
    Wu, Ping
    Zhang, Yingqian
    Song, Mengmeng
    Xu, Chun-Wei
    Shi, Zhe
    Zhang, Ling
    Wang, Yaolin
    Wang, Xicheng
    Zhang, Yiping
    Lu, Shun
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (07) : 940 - 951
  • [48] A phase 1 dose-escalation study of safety, tolerability, and pharmacokinetics (PK) of ABBV-368 monotherapy and combination in patients (pts) with locally advanced or metastatic solid tumors
    Le Tourneau, Christophe
    Su, Wu-Chou
    Chung, Ki
    LoRusso, Patricia
    Lin, Chia-Chi
    Barlesi, Fabrice
    Shiah, Her-Shyong
    Angevin, Eric
    Spira, Alexander
    Patnaik, Amita
    Powderly, John
    Colevas, Dimitrios
    Chew, Helen
    Patel, Maulik
    Lambert, Stacie
    Li, Yan
    Da Costa, Daniel
    Blaney, Martha
    McDevitt, Michael
    Cassier, Philippe
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [49] Phase I study to assess the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of SC10914 in patients with advanced solid tumors.
    Gong, Jifang
    Tang, Jinhai
    Yin, Yongmei
    Ye, Dingwei
    Zhang, Jian
    Zheng, Hong
    Gao, Yunong
    Jang, Haoyuan
    Chen, Xiao
    Zhang, Zhe
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [50] A phase I clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of FN-1501 monotherapy in patients with advanced solid tumors.
    Richardson, Gary Edward
    Vaishampayan, Ulka N.
    Lin, Lin
    Bozon, Viviana
    Hui, Ai-Min
    Williamson, Stephen K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345